The novel agent, along with standard second-line therapy, may allow patients to stay off treatment for longer periods and may have disease modifying effects when used early in the course of disease.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/ianalumab-prolongs-time-treatment-failure-primary-itp-2025a1000yx2?src=rss
Author :
Publish date : 2025-12-12 11:43:00
Copyright for syndicated content belongs to the linked Source.
